when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Alfa · news · pharmadog

← back to Alfa

News mentioning Alfa

100 stories

5dNo ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reinsbiospace

5dRoche cuts muscle-sparing obesity drug after mid-stage disappointmentbiospace

6dKodiak skyrockets on positive study data for 2 eye drugsbiopharma dive

7dTolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drugfiercebiotech

10dEli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalrybiospace

Aug 26, 26Biohaven could get up to $795M in epilepsy alliance with SK Biobiospace

Aug 24, 26Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drugfiercebiotech

Aug 19, 26Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion proteinfiercebiotech

Aug 13, 26Chutes & Ladders—Former Legend CEO lands at K2fiercebiotech

Jul 28, 26GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardfiercebiotech

Jul 27, 26‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drugfiercebiotech

Jul 22, 26Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsbiospace

Jul 17, 26Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Miradorfiercebiotech

Jun 30, 26Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programbiopharma dive

Jun 5, 26Generic drugmakers gain key victory in ‘skinny label’ patent casebiopharma dive

May 13, 26Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practiceonclive

May 13, 26FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLonclive

May 13, 26FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphomaonclive

May 13, 26Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLonclive

May 13, 26Future Directions in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Treatment Sequencing in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumorsonclive

← prevpage 1 of 4next →